estradiol valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
estrogens 1064 979-32-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • estradiol valerate
  • estraval
  • femogex
  • neofollin
  • valergen
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids
  • Molecular weight: 356.51
  • Formula: C23H32O3
  • CLOGP: 6.32
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.76
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 3 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.436 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.543 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 31.842 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 83.946 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 0.440 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 0.880 % Moderate 0.65
herg hERG pIC50 4.944 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 363.078 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 157.036 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 0.530 % Moderate 0.65
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,TEK,TGFBR1 29
kinase-selectivity-class EIF2AK3,GRK2 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.310 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 557.186 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 0.730 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.571 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 1.620 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 352.371 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 8.870 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 0.600 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 4.036 uM Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
July 15, 1954 FDA PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 126.10 36.31 28 1756 5834 90620829
Vestibular migraine 66.12 36.31 10 1774 242 90626421
Endometrial cancer 54.83 36.31 13 1771 3599 90623064
Therapeutic response changed 49.61 36.31 10 1774 1307 90625356
Migraine 49.49 36.31 36 1748 190356 90436307
Ear congestion 45.09 36.31 11 1773 3431 90623232
Multiple lentigines syndrome 44.90 36.31 7 1777 208 90626455
Diabetic retinal oedema 40.18 36.31 7 1777 415 90626248
Bipolar disorder 38.82 36.31 12 1772 8973 90617690
Cataract subcapsular 36.34 36.31 7 1777 724 90625939

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 135.58 36.63 28 1668 5332 110582271
Migraine 50.82 36.63 32 1664 171620 110415983
Ear congestion 47.13 36.63 11 1685 3654 110583949
Multiple lentigines syndrome 45.42 36.63 7 1689 249 110587354
Diabetic retinal oedema 41.57 36.63 7 1689 437 110587166
Vestibular migraine 40.15 36.63 6 1690 173 110587430

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0447348 Estradiol Congeners
FDA MoA N0000000100 Estrogen Receptor Agonists
MeSH PA D004967 Estrogens
MeSH PA D006728 Hormones
FDA EPC N0000175825 Estrogen
CHEBI has role CHEBI:50114 estrogen
CHEBI has role CHEBI:77746 human metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Primary ovarian failure indication 65846009
Menopausal flushing indication 198436008
Advanced Prostatic Carcinoma indication
Metastatic Prostate Carcinoma indication
Polycystic ovaries off-label use 69878008
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Gynecomastia contraindication 4754008 DOID:12698
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Heart disease contraindication 56265001 DOID:114
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Uterine leiomyoma contraindication 95315005 DOID:13223
Neoplasm of prostate contraindication 126906006 DOID:10283
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Endometriosis contraindication 129103003
Bed-ridden contraindication 160685001
Mammography abnormal contraindication 168750009
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Breast Carcinoma in Males contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle To increase rate of weight gain Indication
Cattle To improve feed efficiency Indication
Cattle Synchronization of estrus/ovulation Indication

🐶 Veterinary products

ProductApplicantIngredients
Syncro-Mate-B Boehringer lngelheim Animal Health USA Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.13 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A NATAZIA BAYER HLTHCARE N022252 May 6, 2010 RX TABLET ORAL 8071577 May 13, 2026 PREVENTION OF PREGNANCY
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A NATAZIA BAYER HLTHCARE N022252 May 6, 2010 RX TABLET ORAL 8153616 Jan. 30, 2028 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4017607 VUID
N0000179123 NUI
D01413 KEGG_DRUG
4017607 VANDF
4017609 VANDF
4021205 VANDF
C0059623 UMLSCUI
CHEBI:31561 CHEBI
EST PDB_CHEM_ID
CHEMBL1511 ChEMBL_ID
DB13956 DRUGBANK_ID
D004958 MESH_DESCRIPTOR_UI
13791 PUBCHEM_CID
7655 IUPHAR_LIGAND_ID
3921 INN_ID
OKG364O896 UNII
DB00783 DRUGBANK_ID
24395 RXNORM
4684 MMSL
4686 MMSL
6157 MMSL
6947 MMSL
73244 MMSL
756 MMSL
8602 MMSL
d00537 MMSL
001265 NDDF
001269 NDDF
126172005 SNOMEDCT_US
12839006 SNOMEDCT_US
96350008 SNOMEDCT_US
C0014912 UMLSCUI
5757 PUBCHEM_CID
406 INN_ID
CHEBI:16469 CHEBI
OKG364O896 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Estradiol Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9289 INJECTION 10 mg INTRAMUSCULAR ANDA 15 sections
Estradiol Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9290 INJECTION 20 mg INTRAMUSCULAR ANDA 15 sections
Estradiol Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9291 INJECTION 40 mg INTRAMUSCULAR ANDA 15 sections
ESTRADIOL VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 0517-0420 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 26 sections
ESTRADIOL VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 0517-0440 INJECTION, SOLUTION 40 mg INTRAMUSCULAR ANDA 26 sections
Delestrogen HUMAN PRESCRIPTION DRUG LABEL 1 42023-110 INJECTION 10 mg INTRAMUSCULAR NDA 27 sections
Delestrogen HUMAN PRESCRIPTION DRUG LABEL 1 42023-111 INJECTION 20 mg INTRAMUSCULAR NDA 27 sections
Estradiol valerate HUMAN PRESCRIPTION DRUG LABEL 1 70700-273 INJECTION 10 mg INTRAMUSCULAR ANDA 27 sections
Estradiol valerate HUMAN PRESCRIPTION DRUG LABEL 1 70700-274 INJECTION 20 mg INTRAMUSCULAR ANDA 27 sections
Estradiol valerate HUMAN PRESCRIPTION DRUG LABEL 1 70700-275 INJECTION 40 mg INTRAMUSCULAR ANDA 27 sections